Additional clinical trial data later this year on Tesaro's key drug, Niraparib, which targets advanced solid
tumors in
ovarian and breast cancers, could help narrow the valuation gap, the people said.
A newly devised
tumor - specific fluorescent agent and imaging system guided surgeons in real time to remove
additional tumors in
ovarian cancer patients that were not visible without fluorescence or could not be felt during surgery, reports Alexander L. Vahrmeijer MD, PhD, head of the Image - guided Surgery group in the Department of Surgery at Leiden University Medical Center in the Netherlands.